Artivion, INC 8-K filings

Artivion, Inc. has finalized its acquisition of Endospan Ltd., a move that significantly strengthens its position in the aortic arch disease market with the addition of the NEXUS product line.

Artivion shareholders re-elected all director nominees and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Artivion announced the exercise of its option to acquire Endospan for $135 million, following FDA approval of Endospan's Nexus product, alongside reporting Q1 2026 financial results.

Artivion, Inc. announced robust financial results for Q4 and full year 2025, driven by double-digit revenue and EBITDA growth, alongside positive clinical trial data and regulatory progress.

Artivion, Inc. reported exceptionally strong third-quarter 2025 financial results, driven by robust revenue growth and significant adjusted EBITDA increase, leading to raised full-year guidance.

Artivion, Inc. is acquiring two properties in Austin, Texas for $20.5 million to secure its On-X manufacturing operations and support future expansion.

Artivion, Inc. announced an amendment to its credit agreement, extending debt maturities to 2031, reducing interest rates, and securing a new $150 million delayed draw term loan facility.

Artivion, Inc. announced the appointment of Lance A. Berry as Chief Operating Officer, who will also retain his CFO role, and the upcoming retirement of Chief Medical Officer Marshall S. Stanton.

Artivion, Inc. reported robust second-quarter 2025 financial results, exceeding expectations and raising full-year revenue and adjusted EBITDA guidance.

Artivion, Inc. announced the successful closing of privately negotiated exchange agreements, converting approximately $99.54 million of its 4.250% Convertible Senior Notes due 2025 into 4,334,347 shares of common stock and a cash payment for accrued interest, significantly reducing its outstanding debt.

Artivion, Inc. held its 2025 Annual Meeting of Stockholders, where key proposals, including director elections, executive compensation, auditor ratification, and incentive plan funding, were approved.

Artivion, Inc. announces agreements to exchange approximately $94.54 million in principal amount of its 4.250% Convertible Senior Notes due 2025 for common stock.

Artivion's Q1 2025 results show a slight revenue increase and a raised full-year revenue outlook despite a net loss, driven by growth in key product lines and recovery from a cybersecurity incident.

Artivion announces a 10% increase in full-year revenue and a 32% increase in adjusted EBITDA, driven by growth in key product lines and strategic initiatives.

Artivion, Inc. has elected to change the settlement method for its 4.250% Convertible Senior Notes due 2025 to Physical Settlement, meaning conversions will now be settled with shares of common stock.

Artivion has been granted a Humanitarian Device Exemption (HDE) by the FDA for its AMDS Hybrid Prosthesis, the world's first aortic arch remodeling device for acute DeBakey Type I dissections with malperfusion.

Artivion, Inc. reported a cybersecurity incident involving file acquisition and encryption, prompting system shutdowns and an ongoing investigation.

Artivion's third quarter 2024 results show a 9% revenue increase year-over-year, with significant growth in key product lines and adjusted EBITDA.

Artivion reports a strong second quarter in 2024 with a 10% revenue increase and raises its full-year revenue and adjusted EBITDA guidance.

Artivion has amended its agreements with Endospan, providing an additional $25 million in debt financing and adjusting the terms of its purchase option for the company.

Artivion, Inc. has amended its bylaws, primarily focusing on updating and narrowing the advance notice requirements for stockholder nominations and business proposals.

Artivion's stockholders approved an amendment to the company's certificate of incorporation to allow for officer exculpation and elected all nominated directors at the 2024 Annual Meeting.

Artivion announced a 17% increase in first-quarter revenue and raised its full-year revenue guidance, driven by strong growth in tissue processing and stent grafts.

Artivion announced strong financial results for the fourth quarter and full year 2023, exceeding revenue and adjusted EBITDA growth targets.

Artivion, Inc. has entered into a new $350 million credit agreement to refinance existing debt and provide capital for operations and future growth.